我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
6
2 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
已完成
4
66.7%
Enrolling By Invitation
1
16.7%
尚未招募
暂无批准数据
- Bayer will present pivotal Phase III data for gadoquatrane, its investigational low-dose contrast agent for MRI, demonstrating comparable efficacy to standard macrocyclic agents at 60% lower gadolinium dose. - The company introduces Centargo | Cardio, a comprehensive cardiac CT injection system package, and expands its AI capabilities through a new partnership with MIT spin-off Systalyze on the AI Innovation Platform. - Bayer's radiology division, generating €2 billion in sales in 2023, continues to advance its portfolio across contrast media, injection systems, and AI-enabled solutions for improved patient care.
